Last reviewed · How we verify

Alfredo Antonio Chetta — Portfolio Competitive Intelligence Brief

Alfredo Antonio Chetta pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Beclomethasone Dipropionate/Formoterol Fumarate Beclomethasone Dipropionate/Formoterol Fumarate phase 3 Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Glucocorticoid receptor; beta-2 adrenergic receptor Respiratory/Pulmonology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chiesi Farmaceutici S.p.A. · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Sanofi · 1 shared drug class
  4. SkyePharma AG · 1 shared drug class
  5. Teva Branded Pharmaceutical Products R&D, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Alfredo Antonio Chetta:

Cite this brief

Drug Landscape (2026). Alfredo Antonio Chetta — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alfredo-antonio-chetta. Accessed 2026-05-16.

Related